Sun Pharmaceutical Industries Ltd.
NSE: SUNPHARMA
Healthcare · Drug Manufacturers - Specialty & Generic
₹1,748.00 last close on 23 Oct 2026 −0.57%
Research updated
Dr. Reddy's Laboratories Ltd.
NSE: DRREDDYHealthcareDrug Manufacturers - Specialty & Generic
- Last close
- ₹1,229.50
- Day change
- −₹9.50 (−0.77%)vs
- Market cap
- ₹1.02 lakh crIndian rupees
- Research updated
- 3 reports
Follow Dr. Reddy's Laboratories
Create an account, then follow this company for weekday briefs. You will return to Dr. Reddy's Laboratories after signing in.
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Ltd. is a globally recognized pharmaceutical company specializing in the manufacturing and distribution of a wide array of therapeutic substances and active pharmaceutical ingredients (APIs). Established in 1984 and headquartered in Hyderabad, India, the company plays a significant role in the healthcare sector, striving to make affordable medicine accessible worldwide. Dr. Reddy's Laboratories engages in research, development, and commercialization of complex generics, biosimilars, and proprietary products for various therapeutic areas, including gastroenterology, oncology, pain management, and dermatology. The company holds a substantial international presence with distribution extending across the United States, Russia, Europe, and emerging markets. Its diverse product portfolio not only supports critical medical needs but also drives the global push towards accessible healthcare solutions. Dr. Reddy's Laboratories' commitment to compliance, quality, and innovation enhances its standing in the pharmaceutical industry, contributing significantly to its market influence and ensuring the provision of high-quality medications to a broad demographic.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Listing
- NSE: DRREDDY
- Chief executive
- Mr. Erez Israeli M.B.A.
- Employees
- 27,811
- Headquarters
- Hyderabad, India
- ISIN
- INE089A01031
- Website
- drreddys.com
Public research · Report of
Business model & financial foundation
Dr. Reddy's (NSE: DRREDDY), Pharmaceuticals: generics, branded formulations, APIs and biosimilars: revenue of ₹33,593 crore in FY26 (+3.2% on FY25), an EBITDA margin of 22.8%, net profit of ₹4,285 crore and net cash of ₹3,271 crore.
- Revenue, FY26 (₹ crore)
- 33,593
- consolidated
- Revenue growth, FY26
- +3.2%
- on FY25
- EBITDA margin, FY26
- 22.8%
- EBITDA, company reported definition / revenue
- Net profit, FY26 (₹ crore)
- 4,285
- to owners
- Return on equity, FY26
- 11.9%
- on average equity
- Net debt, FY26 (₹ crore)
- -3,271
- Company net debt; negative for disclosed net cash
- Market capitalisation (₹ crore)
- 1,02,416
- at the close of 23 Oct 2026
Company profile
Hyderabad-headquartered global pharmaceutical group founded in 1984. It develops, manufactures and markets generics, branded medicines, biosimilars, OTC/consumer health products and APIs, and provides pharmaceutical contract research/manufacturing services. Global Generics is divided operationally into North America, Europe (including acquired NRT), India and Emerging Markets; PSAI and Others are separate reportable businesses.
| Item | Value |
|---|---|
| Legal name | Dr. Reddy's Laboratories Limited |
| Exchange and ticker | NSE: DRREDDY; BSE: 500124 |
| ISIN | INE089A01031 |
| CIN | L85195TG1984PLC004507 |
| Sector | Healthcare |
| Industry | Pharmaceuticals: generics, branded formulations, APIs and biosimilars |
| Headquarters | Hyderabad, India |
| Fiscal year end | March |
| Reporting basis and unit | consolidated, in ₹ crore |
| Auditor | S.R. Batliboi & Associates LLP (Indian statutory auditor) |
| Market capitalisation | ₹1,02,416 crore (23 Oct 2026) |
| Shares outstanding | 83.27 crore shares (FY26) |
| Price | ₹1,230 (close, 23 Oct 2026) |
| 52-week range | ₹1,101 - ₹1,415 (to 23 Oct 2026) |
| Website | https://www.drreddys.com/ |
Corporate structure and shareholding
| Entity | Holding | Business |
|---|---|---|
| Dr. Reddy's Laboratories SA | 100% | Swiss international holding and overseas operating structure |
| Dr. Reddy's Laboratories Inc. | 100% | US business; indirectly held through Swiss subsidiary |
| Dr. Reddy's Laboratories Canada, Inc. | 100% | Canadian business; indirectly held through Swiss subsidiary |
| Dr. Reddy's Laboratories (EU) Limited | 100% | European business; indirectly held through Swiss subsidiary |
| betapharm Arzneimittel GmbH | 100% | German generics business via Reddy Holding GmbH |
| Dr. Reddy's Laboratories LLC | 100% | Russia; group holding includes 45.19% direct ownership by listed parent |
| Aurigene Oncology Limited | 100% | Oncology discovery and innovative assets; classified Others |
| Aurigene Pharmaceutical Services Limited | 100% | CDMO services within PSAI; indirectly held via Aurigene Oncology |
| Dr. Reddy's and Nestle Health Science Limited | 51% | Nutrition and nutraceuticals India/Nepal; controlled subsidiary |
| Northstar Switzerland SARL | 100% | Acquired NRT structure; indirect ownership through Swiss subsidiary |
| North Star OpCo Limited | 100% | UK acquired NRT company; held via Northstar Switzerland SARL |
| North Star Sweden AB | 100% | Swedish acquired NRT company; held via Northstar Switzerland SARL |
| Industrias Quimicas Falcon de Mexico, S.A. de CV | 100% | Mexican pharmaceutical/API operations |
| Kunshan Rotam Reddy Pharmaceutical Co. Limited | 51.33% | China joint arrangement; equity accounted, NOT fully consolidated despite legal subsidiary status |
GG (including biologics/NRT), PSAI and Others are reportable segments. GG management geography: NA, Europe incl NRT, India, EM. Holdings at FY26 year-end; material subset, not exhaustive. Kunshan equity-accounted. Svaas divested April 2026.
| Shareholding (% of shares) | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 |
|---|---|---|---|---|
| Promoter | 26.64% | 26.63% | 26.64% | 26.63% |
| Promoter holding pledged | 0.00% | |||
| Foreign institutions | 22.34% | 21.14% | 20.68% | 31.39% |
| Domestic institutions | 30.44% | 30.72% | 31.88% | |
| of which mutual funds | 13.87% | 13.19% | 13.16% | 14.14% |
| Retail | 7.45% | |||
| Other | 2.64% |
The promoter holding pledged is a share of the promoter's own holding.
Business model
Dr. Reddy’s sells branded and generic pharmaceuticals across North America, Europe, India and emerging markets, alongside PSAI (APIs and services). North America is the largest earnings swing factor; India and emerging markets provide the steadier branded/launch-led base. Q2 FY27 showed North America at INR2,489cr, India at INR1,851cr, emerging markets at INR2,060cr and PSAI at INR831cr.
| Segment | revenue, FY26 (₹ crore) | Share |
|---|---|---|
| Global Generics | 29,903 | 89.0% |
| PSAI | 3,477 | 10.4% |
| Others net IFRS management revenue | 212.7 | 0.6% |
Segments as the company reports them (consolidated); each share is of the segments' sum.
| Peer | Why the dossier compares them |
|---|---|
| Sun Pharmaceutical Industries (SUNPHARMA) | India branded formulations and US generics; specialty portfolio creates mix difference. |
| Cipla (CIPLA) | India branded growth, US respiratory/complex generics and emerging-market franchises. |
| Lupin (LUPIN) | US generics launch cycle, complex generics R&D and domestic branded portfolio. |
| Aurobindo Pharma (AUROPHARMA) | Large US/EU generics franchise, API integration and injectable pipeline. |
| Zydus Lifesciences (ZYDUSLIFE) | US generics, domestic formulations, complex products and biosimilars. |
| Torrent Pharmaceuticals (TORNTPHARM) | India and overseas branded franchises; less US exposure, domestic profitability comparator. |
| Alkem Laboratories (ALKEM) | India branded formulations and US generics; domestic growth comparator. |
Financial databook
| Profit and loss (₹ crore) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue (IFRS consolidated) | 21,439 | 24,588 | 27,916 | 32,554 | 33,593 |
| Cost of revenue (vendor classification) * | 10,055 | 10,654 | 11,556 | 13,511 | 15,867 |
| Other operating costs (vendor classification) * | 7,792 | 8,029 | 9,830 | 11,841 | 12,714 |
| EBITDA (vendor classification) * | 4,941 | 7,324 | 8,257 | 9,197 | 7,459 |
| Results from operating activities (IFRS) | 3,326 | 6,180 | 6,773 | 7,184 | 5,055 |
| Gross finance expense (positive expense) | 95.8 | 142.8 | 171.1 | 282.9 | 373.8 |
| Profit before tax | 3,230 | 6,037 | 7,187 | 7,678 | 5,482 |
| Income tax expense, net | 873.0 | 1,530 | 1,619 | 1,954 | 1,235 |
| Profit after tax before NCI allocation | 2,357 | 4,507 | 5,568 | 5,725 | 4,247 |
| Diluted EPS, 1:5 split adjusted (₹) | 66.80 | 67.78 | 51.42 | ||
| Depreciation plus amortization (aggregate IFRS) | 1,182 | 1,264 | 1,484 | 1,706 | 2,061 |
| Cost of revenues, including allocated D&A | 11,556 | 13,511 | 15,867 | ||
| Gross profit after production D&A | 16,361 | 19,043 | 17,726 | ||
| SG&A, including allocated D&A | 7,720 | 9,387 | 10,676 | ||
| R&D, including allocated D&A | 2,287 | 2,738 | 2,406 | ||
| Impairment of non-current assets, net expense | 0.30 | 169.3 | 351.9 | ||
| Other operating income, net (positive income) | 419.9 | 435.8 | 762.7 | ||
| Gross finance income | 570.5 | 755.3 | 787.0 | ||
| Finance income net of finance expense | 399.4 | 472.4 | 413.2 | ||
| Profit of equity-accounted investees, net of tax | 14.7 | 21.7 | 13.4 | ||
| Profit attributable to equity holders of parent | 5,568 | 5,654 | 4,285 | ||
| Profit/(loss) attributable to NCI | 0.00 | 70.1 | -38.4 | ||
| Basic EPS, 1:5 split adjusted (₹) | 66.93 | 67.88 | 51.48 | ||
| EBITDA, company reported definition | 8,301 | 9,213 | 7,660 | ||
| Depreciation charged to income statement | 957.6 | 1,051 | 1,262 | ||
| Amortization charged to income statement | 526.5 | 655.3 | 798.5 | ||
| Employee benefits; already in functional cost lines | 5,030 | 5,580 | 5,991 | ||
| Functional cost of revenues excluding allocated D&A | 10,882 | 12,800 | 15,007 | ||
| SG&A excluding allocated D&A | 7,027 | 8,527 | 9,618 | ||
| R&D excluding allocated D&A | 2,170 | 2,603 | 2,264 | ||
| Separate exceptional-item subtotal (not presented) | n.d. | n.d. | n.d. | ||
| Signed net interest/investment adjustment in EBITDA bridge | -371.6 | -340.2 | -234.7 | ||
| Other expenses | 6,839 | 8,537 | 9,017 |
| Balance sheet (₹ crore) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Total equity including NCI | 19,053 | 23,099 | 28,055 | 33,717 | 38,046 |
| Total borrowings including lease obligations | 2,002 | 4,677 | 7,734 | ||
| Cash and cash equivalents in balance sheet | 1,485 | 577.9 | 710.7 | 1,465 | 1,537 |
| Trade and other receivables, net | 6,676 | 7,249 | 8,030 | 9,042 | 10,122 |
| Inventories, net | 5,088 | 4,867 | 6,355 | 7,109 | 7,653 |
| Trade and other payables (IFRS balance-sheet aggregate) | 3,092 | 3,552 | 3,341 | ||
| Net installed PPE including ROU, excluding CWIP | 6,242 | 7,292 | 10,066 | ||
| Net capital work-in-progress after impairment adjustment | 1,339 | 995.6 | 1,446 | 2,484 | 1,527 |
| Total assets | 29,283 | 32,185 | 38,752 | 49,299 | 57,935 |
| Equity attributable to parent holders | 28,055 | 33,339 | 37,706 | ||
| Non-controlling interests in equity | 0.00 | 377.8 | 339.4 | ||
| Company net debt; negative for disclosed net cash | -6,459 | -2,454 | -3,271 | ||
| Other investments, current | 7,436 | 4,325 | 7,245 | ||
| Other investments, non-current | 105.9 | 1,039 | 1,070 | ||
| Investments including liquid and non-liquid holdings | 7,542 | 5,365 | 8,314 | ||
| Equity investments excluded from company net cash | 119.3 | 147.8 | 275.2 | ||
| Restricted cash deducted in company net cash bridge | 22.7 | 44.1 | 10.9 | ||
| Lease add-back in company net cash reconciliation | 219.0 | 492.1 | 1,441 | ||
| PPE carrying value including net CWIP and ROU | 7,689 | 9,776 | 11,593 | ||
| Total liabilities | 10,697 | 15,582 | 19,889 | ||
| Goodwill | 425.3 | 1,181 | 1,289 | ||
| Other intangible assets | 3,695 | 9,680 | 10,506 | ||
| Investment in equity-accounted investees | 419.6 | 481.1 | 567.3 | ||
| Total current assets | 24,805 | 25,011 | 30,198 | ||
| Total non-current assets | 13,947 | 24,288 | 27,737 | ||
| Total current liabilities | 9,604 | 13,039 | 16,757 | ||
| Total non-current liabilities | 1,093 | 2,543 | 3,132 | ||
| Short-term borrowings | 1,272 | 3,805 | 5,914 | ||
| Long-term borrowings, current portion | 130.7 | 85.7 | 600.3 | ||
| Long-term borrowings, non-current | 599.0 | 786.4 | 1,220 | ||
| Deferred tax assets | 1,077 | 1,851 | 2,244 | ||
| Deferred tax liabilities | 90.9 | 1,411 | 1,557 | ||
| Other current assets | 2,256 | 3,014 | 3,626 | ||
| Other non-current assets | 163.2 | 97.2 | 122.6 | ||
| Investments less equity holdings excluded by company | 7,423 | 5,217 | 8,039 | ||
| Trade-only payables excluding expense and capital creditors | 2,155 | 2,005 | 2,236 | ||
| Total current and non-current lease obligations | 349.7 | 492.1 | 1,441 |
| Cash flow (₹ crore) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| IFRS net cash from operations after cash taxes | 4,543 | 4,643 | 5,676 | ||
| Free cash flow (vendor definition) * | 905.9 | 4,001 | 1,800 | 1,203 | 1,833 |
| Dividends paid (signed outflow) | -414.6 | -497.9 | -664.8 | -666.2 | -665.9 |
| Gross IFRS cash PPE plus intangible purchases (signed) | -1,429 | -1,124 | -2,744 | -3,440 | -3,843 |
| Cash generated from operations before cash taxes | 6,548 | 6,642 | 7,028 | ||
| Income tax paid, net (signed outflow) | -2,005 | -1,999 | -1,353 | ||
| Cash purchase of PPE (signed outflow) | -1,640 | -2,750 | -2,333 | ||
| Cash purchase of other intangible assets (signed) | -1,103 | -689.4 | -1,510 | ||
| Company FCF before acquisitions (release definition) | 2,672 | 1,327 | 2,004 | ||
| IFRS CFO less gross PPE and intangible cash purchases | 1,800 | 1,203 | 1,833 | ||
| PPE/intangible investment outflow in company FCF bridge | -1,871 | -3,315 | -3,672 | ||
| Company cash flow after acquisition payouts | 1,908 | -3,982 | 1,689 | ||
| Cash paid for business acquisitions (signed IFRS) | 0.00 | -5,310 | -315.2 | ||
| Net investing cash flow | -4,028 | -5,808 | -6,551 | ||
| Net financing cash flow | -376.3 | 1,891 | 829.0 | ||
| Net change in CF cash before FX | 138.7 | 726.2 | -46.8 | ||
| Exchange-rate effect on cash | -5.90 | 22.4 | 124.3 | ||
| Cash at start of year, cash-flow basis | 577.9 | 710.7 | 1,459 | ||
| Cash at end of year, net of cash-management overdrafts | 710.7 | 1,459 | 1,537 | ||
| Interest paid, financing cash outflow | -226.6 | -348.3 | -444.1 | ||
| Principal repayment of leases (signed outflow) | -114.7 | -129.4 | -126.3 | ||
| Operating CF change in trade and other receivables | -805.4 | -1,028 | -672.2 | ||
| Operating CF change in inventories | -1,845 | -1,275 | -860.1 | ||
| Operating CF change in trade and other payables | 346.0 | 34.0 | 279.0 | ||
| Operating CF change in other assets/liabilities | 285.7 | -729.3 | 89.7 | ||
| Cash proceeds from sale of PPE | 106.4 | 51.2 | 30.9 | ||
| Cash proceeds from sale of intangible assets | 2.10 | 73.2 | 140.1 | ||
| Net PPE/intangible cash investment after disposal proceeds (signed) | -2,635 | -3,315 | -3,672 |
| Other reported lines (₹ crore) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Year-end equity shares excluding treasury, split-adjusted | 82.94 | 83.02 | 83.26 | 83.20 | 83.27 |
| Year-end issued equity shares including treasury; split-adjusted | 83.41 | 83.45 | 83.47 | ||
| Year-end treasury equity shares; split-adjusted | 0.14 | 0.25 | 0.20 | ||
| Weighted average equity shares for basic EPS | 83.20 | 83.30 | 83.24 | ||
| Weighted average equity shares for diluted EPS | 83.35 | 83.42 | 83.33 | ||
| D&A allocated to cost of revenues | 674.2 | 711.1 | 860.3 | ||
| Depreciation allocated to SG&A | 170.7 | 209.9 | 265.0 | ||
| Amortization allocated to SG&A | 522.0 | 650.2 | 793.4 | ||
| Depreciation allocated to R&D | 112.7 | 129.5 | 136.7 | ||
| Amortization allocated to R&D | 4.50 | 5.10 | 5.10 |
| Quarterly profit and loss (₹ crore) | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue (IFRS consolidated) | 8,359 | 8,506 | 8,545 | 8,805 | 8,727 | 7,516 | 8,071 | 8,698 |
| Cost of revenue (vendor classification) * | 3,453 | 3,780 | 3,213 | 4,317 | ||||
| Other operating costs (vendor classification) * | 3,034 | 2,992 | 2,932 | 3,027 | 3,248 | 3,664 | 3,178 | |
| EBITDA (vendor classification) * | 2,417 | 2,252 | 2,341 | 2,389 | 2,036 | 1,121 | 981.0 | |
| Results from operating activities (IFRS) | 1,872 | 1,765 | 1,748 | 1,751 | 1,424 | 132.5 | 378.4 | |
| Gross finance expense (positive expense) | 81.8 | 65.6 | 83.0 | 90.7 | 94.4 | 105.7 | 125.5 | 124.8 |
| Profit before tax | 1,874 | 2,005 | 1,905 | 1,835 | 1,543 | 199.1 | 552.6 | 1,235 |
| Income tax expense/(benefit), net | 470.4 | 418.1 | 495.1 | 408.2 | 353.3 | -21.4 | 117.8 | 314.4 |
| Profit after tax before NCI allocation | 1,404 | 1,587 | 1,410 | 1,427 | 1,190 | 220.5 | 434.8 | 913.2 |
| Diluted EPS, 1:5 split adjusted (not annualized) (₹) | 16.94 | 19.11 | 17.02 | 17.25 | 14.52 | 2.64 | 5.32 | 11.09 |
| Aggregate D&A, sum of company EBITDA bridge components | 471.9 | 455.5 | 476.5 | 505.1 | 521.5 | 557.6 | 537.2 | |
| Cost of revenues, including allocated D&A | 3,453 | 3,780 | 3,683 | 3,991 | 4,046 | 4,147 | 4,317 | |
| Gross profit after production D&A | 4,905 | 4,726 | 4,863 | 4,814 | 4,681 | 3,369 | 3,754 | |
| SG&A, including allocated D&A | 2,412 | 2,406 | 2,565 | 2,644 | 2,692 | 2,776 | 2,882 | |
| R&D, including allocated D&A | 665.8 | 725.8 | 624.4 | 620.2 | 614.9 | 546.3 | 576.6 | |
| Impairment of non-current assets, net expense | -0.40 | 76.8 | 0.00 | 66.2 | 27.1 | 258.6 | 1.50 | |
| Other operating income, net (positive income) | 43.9 | 246.5 | 73.9 | 267.3 | 77.0 | 344.5 | 84.5 | 156.2 |
| Gross finance income | 79.8 | 300.8 | 240.0 | 168.1 | 211.2 | 167.7 | 298.9 | |
| Profit attributable to equity holders of parent | 1,413 | 1,594 | 1,418 | 1,437 | 1,210 | 220.1 | 443.5 | 924.8 |
| Profit/(loss) attributable to NCI | -9.50 | -6.60 | -8.20 | -10.4 | -20.2 | 0.40 | -8.70 | -11.6 |
| Profit of equity-accounted investees, net of tax | 4.20 | 5.50 | 0.20 | 6.30 | 2.30 | 4.60 | 0.80 | -7.70 |
| Finance income/(expense), net | -2.00 | 235.2 | 157.0 | 77.4 | 116.8 | 62.0 | 173.4 | |
| EBITDA, company reported definition | 2,298 | 2,475 | 2,278 | 2,351 | 2,049 | 980.7 | 1,009 | 1,731 |
| Depreciation, company EBITDA bridge | 273.3 | 263.6 | 289.4 | 309.1 | 317.8 | 345.9 | 338.0 | |
| Amortization, company EBITDA bridge | 198.6 | 191.9 | 187.1 | 196.0 | 203.7 | 211.7 | 199.2 | |
| Signed net interest/investment adjustment in EBITDA bridge | -47.5 | -62.7 | -102.8 | -55.2 | -42.2 | -34.6 | -82.5 | |
| Functional cost of revenues excluding allocated D&A | n.r. | n.r. | n.r. | n.r. | n.r. | n.r. | n.r. | |
| SG&A excluding allocated D&A | n.r. | n.r. | n.r. | n.r. | n.r. | n.r. | n.r. | |
| R&D excluding allocated D&A | n.r. | n.r. | n.r. | n.r. | n.r. | n.r. | n.r. | |
| Separate exceptional-item subtotal (not presented) | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | |
| Employee benefit expense | 1,367 | 1,401 | 1,504 | 1,452 | 1,589 | 1,447 | 1,652 | 1,612 |
| Other expenses | 2,160 | 2,280 | 2,088 | 2,243 | 2,182 | 2,504 | 2,203 | 2,187 |
| Basic EPS (₹) | 16.97 | 19.12 | 17.04 | 16.18 | 14.53 | 2.65 | 5.33 | 11.10 |
Consolidated, as reported. Lines marked * are the market-data provider's figures; the rest are extracted from the company's filings or derived from them. n.d. not disclosed, n.r. not retrieved, n.a. not applicable.
Metrics dashboard
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue growth | 13.0% | 14.7% | 13.5% | 16.6% | 3.2% |
| EBITDA margin | 29.7% | 28.3% | 22.8% | ||
| Net margin | 19.9% | 17.4% | 12.8% | ||
| Return on equity | 21.8% | 18.3% | 11.9% | ||
| Return on capital employed | 22.5% | 21.0% | 12.0% | ||
| Return on assets | 15.7% | 12.8% | 8.0% | ||
| Net debt (₹ crore) | -6,459 | -2,454 | -3,271 | ||
| Net debt / EBITDA | -0.78x | -0.27x | -0.43x | ||
| Interest cover | 34.7x | 43.3x | 39.6x | 25.4x | 13.5x |
| Asset turnover | 0.77x | 0.80x | 0.79x | 0.74x | 0.63x |
| Receivable days | 114 | 108 | 105 | 101 | 110 |
| Inventory days (on revenue) | 87 | 72 | 83 | 80 | 83 |
| Payable days (on revenue) | 40 | 40 | 36 | ||
| Cash conversion | 0.82x | 0.82x | 1.32x | ||
| Capex intensity | 6.7% | 4.6% | 9.8% | 10.6% | 11.4% |
| Free cash flow (₹ crore) | 1,800 | 1,203 | 1,833 | ||
| Dividend payout | 11.9% | 11.8% | 15.5% | ||
| EPS, diluted (₹) | 66.80 | 67.78 | 51.42 | ||
| Book value per share (₹) | 229.7 | 278.2 | 336.9 | 405.2 | 456.9 |
Computed from the statements above:
- Revenue growth: revenue over the previous year's, less one.
- EBITDA margin: EBITDA, company reported definition / revenue.
- Net margin: net profit to owners / revenue.
- Return on equity: net profit to owners / average equity.
- Return on capital employed: EBIT / average equity plus borrowings.
- Return on assets: net profit to owners / average total assets.
- Net debt (₹ crore): Company net debt; negative for disclosed net cash.
- Net debt / EBITDA: net debt / EBITDA, company reported definition.
- Interest cover: EBIT / finance cost.
- Asset turnover: revenue / average total assets.
- Receivable days: receivables / revenue x 365.
- Inventory days (on revenue): inventory / revenue x 365.
- Payable days (on revenue): payables / revenue x 365.
- Cash conversion: cash from operations / net profit to owners.
- Capex intensity: capital expenditure / revenue.
- Free cash flow (₹ crore): cash from operations less capital expenditure.
- Dividend payout: dividends paid / net profit to owners.
- EPS, diluted (₹): as reported (Diluted EPS, 1:5 split adjusted).
- Book value per share (₹): equity / shares outstanding.
Source: the company's filings and disclosures as extracted into Mool's company dossier (version 3, information to 23 Oct 2026); market data at the close of 23 Oct 2026. Every figure is read from the dossier's files or computed from them; the account of the business model is the analyst's, from the dossier's workings.
With Individual or above
What the full research on Dr. Reddy's Laboratories includes
Every piece of Mool’s research is built the same way: a researched evidence base, analyses that build on each other, a research model and a report with the call. This page shows the first analysis.
The report and Mool’s call
- The 12-month rating and target
- The 3-month view
- Mool's estimates beside the street's
- The claims the view rests on, and what would change it
The analyses, among them
- Business model & financial foundationOn this pageWhat the company does and how it makes money, its structure, five years of financials and the metrics that matter for it.
- Future earnings & financial modelForecasts built from the drivers that move the business, by scenario, beside the street's.
- Fundamental valuation & 12-month thesisWhat the business is worth on several methods, what the market already prices in and the 12-month thesis that follows.
The research model
The model behind the report: the company’s history, the drivers that move it, its forecasts by scenario and the valuation the 12-month target comes from.
See Mool’s call and the full research
Individual or above opens every piece of research Mool has published. A new account can start with 10 days of Pro, or of Firm on a work email address. No card needed.
Report history
Reports on Dr. Reddy's Laboratories
- Research reportLatest
- Research report
- Research report
Same sector
More research in Healthcare
Divi's Laboratories Ltd.
NSE: DIVISLAB
Healthcare · Drug Manufacturers - Specialty & Generic
₹8,950.00 last close on 23 Oct 2026 −2.31%Research updated
Torrent Pharmaceuticals Ltd.
NSE: TORNTPHARM
Healthcare · Drug Manufacturers - Specialty & Generic
₹4,524.40 last close on 23 Oct 2026 −1.97%Research updated
Apollo Hospitals Enterprise Ltd.
NSE: APOLLOHOSP
Healthcare · Medical Care Facilities
₹7,730.00 last close on 23 Oct 2026 +1.65%Research updated
Lenskart Solutions Limited
NSE: LENSKART
Healthcare · Medical Instruments & Supplies
₹626.45 last close on 23 Oct 2026 −1.23%Research updated
Zydus Lifesciences Ltd.
NSE: ZYDUSLIFE
Healthcare · Drug Manufacturers - Specialty & Generic
₹1,129.40 last close on 23 Oct 2026 −0.49%Research updated
Prices are the last close on the NSE, 23 Oct 2026. Research from Mool’s report of 23 Oct 2026; page updated 25 Oct 2026.
Mool’s research is written by AI agents and published by Mool Capital Private Limited, a SEBI-registered Research Analyst, registration INH000012449, which is responsible for it. This page shows factual company information and an excerpt of that research; it carries no rating and is not investment advice for any individual. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Read the disclosures.